Bicara Therapeutics Raises $172.5M in Public Offering with Full Option Exercise
Bicara Therapeutics raised $172.5 million by selling 8.58 million common shares and warrants for 2.2 million shares at $16.00 each, including full underwriter option exercise. Net proceeds will support ficerafusp alfa’s US regulatory filing and commercial launch preparations, accelerate HPV-negative HNSCC development, fund manufacturing and future indication trials.
1. Offering Details
On February 26, 2026, Bicara Therapeutics completed an underwritten public offering of 8,581,250 common shares and pre-funded warrants for 2,200,000 shares at $16.00 per unit, raising $172.5 million gross. The underwriters fully exercised their option to purchase an additional 1,406,250 shares, reflecting strong investor demand.
2. Use of Proceeds
Bicara plans to deploy net proceeds to build medical and commercial infrastructure supporting a planned US regulatory filing and potential launch of ficerafusp alfa. Funds will also accelerate development in first-line recurrent/metastatic HPV-negative head and neck cancer, cover manufacturing costs, and support trials for new indications.
3. Strategic Implications
This financing strengthens Bicara’s balance sheet, reduces near-term funding risks, and enables advancement of its bifunctional antibody platform. Enhanced capital position may de-risk clinical milestones and position ficerafusp alfa for pivotal regulatory and commercial stages.